source
- Biotech firms EMD Serono and Exelixis cut remote R&D staff as they enforce office return policiesBiopharma workers at two biotech companies are losing jobs as employers shift away from remote work. The changes affect research and development staff who were previously allowed to work from home.…
- FDA rejects Osteal Therapeutics' combo therapy for joint-implant infectionsThe U.S. Food and Drug Administration rejected Osteal Therapeutics' lead combination therapy late last month. The agency cited concerns that prevented approval of the product intended to treat infe…